tiprankstipranks
Dyne Therapeutics, Inc. (DYN)
NASDAQ:DYN
US Market
DYN
Dyne Therapeutics
RESEARCH TOOLSreports
Want to see DYN full AI Analyst Report?

Dyne Therapeutics (DYN) Stock Forecast & Price Target

473 Followers
See the Price Targets and Ratings of:

DYN Analyst Ratings

Strong Buy
10Ratings
Strong Buy
9 Buy
1 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Dyne
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

DYN Stock 12 Month Forecast

Average Price Target

$40.33
▲(97.62% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Dyne Therapeutics in the last 3 months. The average price target is $40.33 with a high forecast of $50.00 and a low forecast of $24.00. The average price target represents a 97.62% change from the last price of $20.41.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","18":"$18","29":"$29","40":"$40","51":"$51"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$50.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40.33333333333333,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$40.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$24.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,18,29,40,51],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.79,23.96,26.13,28.299999999999997,30.47,32.64,34.81,36.98,39.15,41.32,43.489999999999995,45.66,47.83,{"y":50,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.79,23.216410256410256,24.64282051282051,26.069230769230767,27.495641025641024,28.922051282051278,30.348461538461535,31.774871794871792,33.20128205128205,34.6276923076923,36.054102564102564,37.480512820512814,38.90692307692307,{"y":40.33333333333333,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.79,21.96,22.13,22.3,22.47,22.64,22.81,22.98,23.15,23.32,23.49,23.66,23.83,{"y":24,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.68,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.05,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.5,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.5,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.58,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.61,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.56,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.76,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.15,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.1,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.39,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.63,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.79,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$50.00Average Price Target$40.33Lowest Price Target$24.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Guggenheim Analyst forecast on DYN
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
$50
Buy
144.98%
Upside
Reiterated
06/30/26
Guggenheim Reaffirms Their Buy Rating on Dyne Therapeutics (DYN)
TD Cowen Analyst forecast on DYN
Joseph Thome
TD Cowen
TD Cowen
―
Buy
―
Initiated
06/26/26
Joseph Thome Initiates Buy on Dyne Therapeutics, Citing Late-Stage Pipeline Strength and Multi-Billion-Dollar Peak Sales Potential
LifeSci Capital Analyst forecast on DYN
Francois Brisebois
LifeSci Capital
LifeSci Capital
$44
Buy
115.58%
Upside
Reiterated
06/24/26
Analysts' Top Healthcare Picks: Dyne Therapeutics (DYN), Argenx Se (ARGX)
Evercore ISI Analyst forecast on DYN
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
$33
Buy
61.69%
Upside
Reiterated
06/04/26
Analysts Offer Insights on Healthcare Companies: Medtronic (NYSE: MDT), Arcus Biosciences (NYSE: RCUS) and Dyne Therapeutics (NASDAQ: DYN)
Morgan Stanley Analyst forecast on DYN
Michael Ulz
Morgan Stanley
Morgan Stanley
$47
Buy
130.28%
Upside
Reiterated
06/03/26
Analysts Offer Insights on Healthcare Companies: Veeva Systems (NYSE: VEEV), Dyne Therapeutics (NASDAQ: DYN) and Argenx Se (NASDAQ: ARGX)
H.C. Wainwright Analyst forecast on DYN
Ananda Ghosh
H.C. Wainwright
H.C. Wainwright
$50
Buy
144.98%
Upside
Reiterated
05/21/26
Analyst Maintains Buy Rating on Dyne, Keeps $50 Price Target on Strength of FORZETTO Study Design and Z‑Rostudirsen Data
Chardan Capital Analyst forecast on DYN
Andreas Argyrides
Chardan Capital
Chardan Capital
$40
Buy
95.98%
Upside
Reiterated
05/21/26
Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (NASDAQ: DYN) and Palvella Therapeutics (NASDAQ: PVLA)
Piper Sandler Analyst forecast on DYN
Edward Tenthoff
Piper Sandler
Piper Sandler
$45
Buy
120.48%
Upside
Reiterated
05/14/26
Piper Sandler Remains a Buy on Dyne Therapeutics (DYN)
Bernstein Analyst forecast on DYN
William Pickering
Bernstein
Bernstein
$23→$24
Hold
17.59%
Upside
Assigned
05/13/26
Dyne Therapeutics price target raised to $24 from $23 at BernsteinDyne Therapeutics price target raised to $24 from $23 at Bernstein
RBC Capital Analyst forecast on DYN
Luca Issi
RBC Capital
RBC Capital
$30
Buy
46.99%
Upside
Reiterated
05/11/26
RBC Capital Reaffirms Their Buy Rating on Dyne Therapeutics (DYN)
J.P. Morgan Analyst forecast on DYN
Tessa Romero
J.P. Morgan
J.P. Morgan
$16
Hold
-21.61%
Downside
Reiterated
03/16/26
J.P. Morgan Reaffirms Their Hold Rating on Dyne Therapeutics (DYN)
Stifel Nicolaus Analyst forecast on DYN
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$36
Buy
76.38%
Upside
Reiterated
12/15/25
Dyne Therapeutics (DYN) Gets a Buy from Stifel Nicolaus
Raymond James Analyst forecast on DYN
Martin Auster
Raymond James
Raymond James
$31→$35
Buy
71.48%
Upside
Reiterated
08/25/25
Dyne Therapeutics upgraded to Strong Buy from Outperform at Raymond JamesDyne Therapeutics upgraded to Strong Buy from Outperform at Raymond James
Scotiabank Analyst forecast on DYN
Louise Chen
Scotiabank
Scotiabank
$50
Buy
144.98%
Upside
Reiterated
07/29/25
Dyne Therapeutics (DYN) Gets a Buy from Scotiabank
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Guggenheim Analyst forecast on DYN
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
$50
Buy
144.98%
Upside
Reiterated
06/30/26
Guggenheim Reaffirms Their Buy Rating on Dyne Therapeutics (DYN)
TD Cowen Analyst forecast on DYN
Joseph Thome
TD Cowen
TD Cowen
―
Buy
―
Initiated
06/26/26
Joseph Thome Initiates Buy on Dyne Therapeutics, Citing Late-Stage Pipeline Strength and Multi-Billion-Dollar Peak Sales Potential
LifeSci Capital Analyst forecast on DYN
Francois Brisebois
LifeSci Capital
LifeSci Capital
$44
Buy
115.58%
Upside
Reiterated
06/24/26
Analysts' Top Healthcare Picks: Dyne Therapeutics (DYN), Argenx Se (ARGX)
Evercore ISI Analyst forecast on DYN
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
$33
Buy
61.69%
Upside
Reiterated
06/04/26
Analysts Offer Insights on Healthcare Companies: Medtronic (NYSE: MDT), Arcus Biosciences (NYSE: RCUS) and Dyne Therapeutics (NASDAQ: DYN)
Morgan Stanley Analyst forecast on DYN
Michael Ulz
Morgan Stanley
Morgan Stanley
$47
Buy
130.28%
Upside
Reiterated
06/03/26
Analysts Offer Insights on Healthcare Companies: Veeva Systems (NYSE: VEEV), Dyne Therapeutics (NASDAQ: DYN) and Argenx Se (NASDAQ: ARGX)
H.C. Wainwright Analyst forecast on DYN
Ananda Ghosh
H.C. Wainwright
H.C. Wainwright
$50
Buy
144.98%
Upside
Reiterated
05/21/26
Analyst Maintains Buy Rating on Dyne, Keeps $50 Price Target on Strength of FORZETTO Study Design and Z‑Rostudirsen Data
Chardan Capital Analyst forecast on DYN
Andreas Argyrides
Chardan Capital
Chardan Capital
$40
Buy
95.98%
Upside
Reiterated
05/21/26
Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (NASDAQ: DYN) and Palvella Therapeutics (NASDAQ: PVLA)
Piper Sandler Analyst forecast on DYN
Edward Tenthoff
Piper Sandler
Piper Sandler
$45
Buy
120.48%
Upside
Reiterated
05/14/26
Piper Sandler Remains a Buy on Dyne Therapeutics (DYN)
Bernstein Analyst forecast on DYN
William Pickering
Bernstein
Bernstein
$23→$24
Hold
17.59%
Upside
Assigned
05/13/26
Dyne Therapeutics price target raised to $24 from $23 at BernsteinDyne Therapeutics price target raised to $24 from $23 at Bernstein
RBC Capital Analyst forecast on DYN
Luca Issi
RBC Capital
RBC Capital
$30
Buy
46.99%
Upside
Reiterated
05/11/26
RBC Capital Reaffirms Their Buy Rating on Dyne Therapeutics (DYN)
J.P. Morgan Analyst forecast on DYN
Tessa Romero
J.P. Morgan
J.P. Morgan
$16
Hold
-21.61%
Downside
Reiterated
03/16/26
J.P. Morgan Reaffirms Their Hold Rating on Dyne Therapeutics (DYN)
Stifel Nicolaus Analyst forecast on DYN
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$36
Buy
76.38%
Upside
Reiterated
12/15/25
Dyne Therapeutics (DYN) Gets a Buy from Stifel Nicolaus
Raymond James Analyst forecast on DYN
Martin Auster
Raymond James
Raymond James
$31→$35
Buy
71.48%
Upside
Reiterated
08/25/25
Dyne Therapeutics upgraded to Strong Buy from Outperform at Raymond JamesDyne Therapeutics upgraded to Strong Buy from Outperform at Raymond James
Scotiabank Analyst forecast on DYN
Louise Chen
Scotiabank
Scotiabank
$50
Buy
144.98%
Upside
Reiterated
07/29/25
Dyne Therapeutics (DYN) Gets a Buy from Scotiabank
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
OCGNOcugen
TARAProtara Therapeutics
MIRMMirum Pharmaceuticals
CSTLCastle Biosciences
PCVXVaxcyte
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Dyne Therapeutics

3 Months
Paul MatteisStifel Nicolaus
Success Rate
14/24 ratings generated profit
58%
Average Return
+8.96%
Copying Paul Matteis's trades and holding each position for 3 Months would result in 58.33% of your transactions generating a profit, with an average return of +8.96% per trade.
1 Year
Michael UlzMorgan Stanley
Success Rate
12/19 ratings generated profit
63%
Average Return
+13.85%
Copying Michael Ulz's trades and holding each position for 1 Year would result in 63.16% of your transactions generating a profit, with an average return of +13.85% per trade.
2 Years
Michael UlzMorgan Stanley
Success Rate
12/19 ratings generated profit
63%
Average Return
+34.37%
Copying Michael Ulz's trades and holding each position for 2 Years would result in 63.16% of your transactions generating a profit, with an average return of +34.37% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

DYN Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
10
10
24
20
19
Buy
0
0
0
1
1
Hold
1
1
2
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
11
11
26
22
21
In the current month, DYN has received 20 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. DYN average Analyst price target in the past 3 months is 40.33.
Each month's total comprises the sum of three months' worth of ratings.

DYN Financial Forecast

DYN Earnings Forecast

Next quarter’s earnings estimate for DYN is -$0.75 with a range of -$0.84 to -$0.68. The previous quarter’s EPS was -$0.73. DYN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year DYN has Performed in-line its overall industry.
Next quarter’s earnings estimate for DYN is -$0.75 with a range of -$0.84 to -$0.68. The previous quarter’s EPS was -$0.73. DYN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year DYN has Performed in-line its overall industry.
No data currently available

DYN Sales Forecast

Next quarter’s sales forecast for DYN is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. DYN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year DYN has Performed in-line its overall industry.
Next quarter’s sales forecast for DYN is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. DYN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year DYN has Performed in-line its overall industry.

DYN Stock Forecast FAQ

What is DYN’s average 12-month price target, according to analysts?
Based on analyst ratings, Dyne Therapeutics, Inc.’s 12-month average price target is 40.33.
    What is DYN’s upside potential, based on the analysts’ average price target?
    Dyne Therapeutics, Inc. has 97.62% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is DYN a Buy, Sell or Hold?
          Dyne Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 9 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Dyne Therapeutics, Inc.’s price target?
            The average price target for Dyne Therapeutics, Inc. is 40.33. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $50.00 ,the lowest forecast is $24.00. The average price target represents 97.62% Increase from the current price of $20.41.
              What do analysts say about Dyne Therapeutics, Inc.?
              Dyne Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of DYN?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.